Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Iparomlimab and Tuvonralimab (QL1706) Combined Chemotherapy and Quad Shot Radiotherapy in First-line Treatment of Driver Gene-negative Advanced Non-small Cell Lung Cancer: a Randomized, Controlled, Phase 2, Open-label Trial.

NCT07271602 is registered in ClinicalTrials.gov with Union Hospital, Tongji Medical College, Huazhong University of Science and Technology as lead sponsor.

NCT NCT07271602
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07271602 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Iparomlimab and Tuvonralimab (QL1706) Combined Chemotherapy and Quad Shot Radiotherapy in First-line Treatment of Driver Gene-negative Advanced Non-small Cell Lung Cancer: a Randomized, Controlled, Phase 2, Open-label Trial.
Lead sponsor
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase
Phase 2
Overall status
Not yet recruiting
Start date
January 30, 2026
Completion date
December 31, 2028
Enrollment
104 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

chemotherapy, immunotherapy, non small cell lung cancer, radiotherapy